Baylor Scott & White The Heart Group

Our philosophy

In clinic and hospital settings, research trials are performed with patients who generously give physicians, and those in the cardiovascular research and healthcare industry, the opportunity to further study cardiovascular disease. The cardiologists at Baylor Scott & White The Heart Group have been active in research for over 20 years, advancing new prevention and treatment options for our patients. These studies are vital and allow us to provide innovative treatments to our patients who are involved in these investigative trials. We are grateful to our patients who take part in them.

Why do we participate in clinical trials?

Our physicians believe that by studying new medications and treatment options for cardiovascular disease, they will be able to offer progressive medical care to their patients.

Participation Criteria

What criteria must the patient meet to participate in a trial?

Each clinical study has specific criteria which the patient must meet. These guidelines relate to the patient’s condition and determine whether he/she is qualified to participate. If considering whether to participate in a study or not, it is best to speak with your physician about any concerns or questions you may have.

If you have a heart-related condition and would like to participate in a trial, speak with your Baylor Scott & White The Heart Group cardiologist first.

Research news

Baylor Hospitals Top U.S. Sites for Hypertension Trial

Current trials

Pioneer II - The Pioneer II study is an open-label, tandomized, controlled, multicenter study exploring two treatment strategies of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention: PIONEER AF-PCI.

Sur-TAVI - Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement.

PVL in TAVR - A Novel Imaging Approach to Assess Paravalvular Leak for Transcatheter Valve Replacement.

Low Dose CT - A Novel Low-dose-contrast Cardiac Computed Tomography Method for Pre-Procedural Guidance in Transcatheter Aortic Valve Replacement.

ABSORB - Resorbable coronary stent-Brown

ISCHEMIA - To determine the best management strategy for patients with stable ischemic heart disease (SIHD) and moderate-to-severe ischemia; routine early invasive strategy (INV) with cardiac catheterization (cath) followed by revascularization plus optimal medical therapy (OMT) is superior to a conservative strategy (CON) of OMT.

SYMPLICITY - Renal denervation for uncontrolled hypertension.

STOP AF PAS - Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)-Gopal

PARTNER II - Placement of Aortic Transcatheter Valves Trial. The Safety and Effectiveness of the SAPIEN XT™ Transcatheter Heart Valve with Novaflex and Ascendra 2 delivery systems (Transfemoral and Transapical) in Intermediate Risk for Aortic Valve Surgery and Patients Who Cannot Undergo Surgery.

Resolute Integrity - A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm

EXCEL - Evaluation of XIENCE PRIME or XIENCE V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.

COAPT - Clinical Outcomes Assessment of the MitraClip Percutaneous Therapy for High Surgical Risk Patients.

EVOLVE II Trial - The purpose of this study is to assess the safety and effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate).

CTOT II Trial -  is an investigative consortium for conducting clinical and associated mechanistic studies that will lead to improved outcomes for transplant recipients. The purpose of these studies is to improve short and long-term graft and patient survival.

PORTICO - is a prospective, multi-center, randomized-controlled clinical study, designed to evaluate the safety and effectiveness of the St. Jude Medical (SJM) Portico Transcatheter Heart Valve and Delivery Systems (Portico) via the transfemoral and transapical delivery methods, in high and extreme risk cohorts.

Direct Flow - is a study to assess the safety and effectiveness of the Direct Flow Medical aortic valve system. This is for people with severe aortic stenosis who are not well enough to undergo a surgical repair.